Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders

Show full item record



Permalink

http://hdl.handle.net/10138/224172

Citation

Fisher , M L , Loukola , A , Kaprio , J & Turner , J R 2015 , Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders . in M DeBiasi (ed.) , NICOTINE USE IN MENTAL ILLNESS AND NEUROLOGICAL DISORDERS . 1. p. edn , International Review of Neurobiology , vol. 124 , ACADEMIC PRESS INC ELSEVIER SCIENCE , pp. 113-131 . https://doi.org/10.1016/bs.irn.2015.07.006

Title: Role of the Neuregulin Signaling Pathway in Nicotine Dependence and Co-morbid Disorders
Author: Fisher, Miranda L.; Loukola, Anu; Kaprio, Jaakko; Turner, Jill R.
Editor: DeBiasi, Mariella
Contributor: University of Helsinki, Clinicum
University of Helsinki, Clinicum
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE
Date: 2015
Language: eng
Number of pages: 19
Belongs to series: NICOTINE USE IN MENTAL ILLNESS AND NEUROLOGICAL DISORDERS
Belongs to series: International Review of Neurobiology
ISBN: 978-0-12-801583-4
9780128016268
URI: http://hdl.handle.net/10138/224172
Abstract: Smoking is currently the leading cause of preventable death in the United States and is responsible for over four million deaths annually worldwide. Therefore, there is a vast clinical unmet need with regards to therapeutics targeting smoking cessation. This is even more apparent when examining smokers co-morbid with psychiatric illness, as rates of smoking in this population are similar to 4 x higher than in the general population. Examining common genetic and molecular signaling pathways impinging upon both smoking behavior and psychiatric illness will lead to a better understanding of co-morbid disorders and potential development of novel therapeutics. Studies have implicated the Neuregulin Signaling Pathway in the pathophysiology of a number of psychiatric illnesses. Additionally, recent studies have also shown an association between the Neuregulin Signaling Pathway and smoking behaviors. This review outlines basic mechanisms of the Neuregulin Signaling Pathway and how it may be exploited for precision medicine approaches in treating nicotine dependence and mental illness.
Subject: SUSTAINED-RELEASE BUPROPION
RANDOMIZED CONTROLLED-TRIAL
RECEPTOR TYROSINE KINASE
SMOKING-CESSATION
CIGARETTE-SMOKING
SUSCEPTIBILITY LOCI
MAJOR DEPRESSION
BIPOLAR DISORDER
PARTIAL AGONIST
NERVOUS-SYSTEM
3112 Neurosciences
3124 Neurology and psychiatry
3142 Public health care science, environmental and occupational health
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0074774215000525_main.pdf 371.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record